ABBVIE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25 CAD | +1.46% |
|
+0.36% | +10.28% |
| 02:58pm | AbbVie Says Robert Michael Assumes CEO Role | MT |
| 02:00pm | AbbVie Announces Board Changes | CI |
| Sales 2024 * | 55.2B 75.65B | Sales 2025 * | 58.19B 79.75B | Capitalization | 303B 415B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.6B 11.79B | Net income 2025 * | 11.44B 15.67B | EV / Sales 2024 * | 6.52 x |
| Net Debt 2024 * | 56.89B 77.96B | Net Debt 2025 * | 47.91B 65.66B | EV / Sales 2025 * | 6.03 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
23.5
x | Employees | 50,000 |
| Yield 2024 * |
3.63% | Yield 2025 * |
3.79% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
| 1 day | +1.46% | ||
| 1 week | +0.36% | ||
| 1 month | +6.25% | ||
| 3 months | -6.12% | ||
| 6 months | +10.28% | ||
| Current year | +10.28% |
1 week
24.51
25.11
1 month
23.2225.26
Current year
22.4426.67
1 year
19.6526.67
3 years
19.4526.67
5 years
19.4526.67
10 years
19.4526.67
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
| Director/Board Member | 70 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 25 | +1.46% | 15,864 |
| 24-06-27 | 24.64 | -1.87% | 6,349 |
| 24-06-26 | 25.11 | +0.76% | 5,530 |
| 24-06-25 | 24.92 | -1.35% | 37,456 |
| 24-06-24 | 25.26 | +1.41% | 8,522 |
End-of-day quote NEO Exchange, June 27, 2024
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-07-14
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.5
USD
Average target price
183.2
USD
Spread / Average Target
+6.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.46% | 815B | |
| +43.09% | 641B | |
| -5.65% | 352B | |
| +17.81% | 314B | |
| +16.47% | 242B | |
| +2.37% | 224B | |
| +13.90% | 218B | |
| +9.55% | 168B | |
| -0.78% | 159B |
- Stock Market
- Equities
- ABBV Stock
- ABBV Stock
